Cantabio Pharmaceuticals Inc., of Palo Alto, Calif., completed a reverse merger with Gardedam Therapeutics Inc., also of Palo Alto. Cantabio will have an exclusive focus on the discovery and development of Gardedam’s drug pipeline for neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases.